Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB (original) (raw)

• Melief, C.J. & Kast, W.M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145, 167–177 (1995).
  Article CAS PubMed Google Scholar
• Riddell, S.R. & Greenberg, P.D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13, 545–586 (1995).
  Article CAS PubMed Google Scholar
• Riddell, S.R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238–241 (1992).
  Article CAS PubMed Google Scholar
• Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637–1644 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Brodie, S.J. et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5, 34–41 (1999).
  Article CAS PubMed Google Scholar
• Riddell, S.R. et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum. Gene Ther. 3, 319–338 (1992).
  Article CAS PubMed Google Scholar
• Riddell, S.R. & Greenberg, P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 128, 189–201 (1990).
  Article CAS PubMed Google Scholar
• Heslop, H.E. et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551–555 (1996).
  Article CAS PubMed Google Scholar
• Levine, B.L. et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921–5930 (1997).
  CAS PubMed Google Scholar
• Deeths, M.J., Kedl, R.M. & Mescher, M.F. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J. Immunol. 163, 102–110 (1999).
  CAS PubMed Google Scholar
• Laux, I. et al. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin. Immunol. 96, 187–197 (2000).
  Article CAS PubMed Google Scholar
• Deeths, M.J. & Mescher, M.F. B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur. J. Immunol. 27, 598–608 (1997).
  Article CAS PubMed Google Scholar
• Pollok, K.E. et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J. Immunol. 150, 771–781 (1993).
  CAS PubMed Google Scholar
• Goodwin, R.G. et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 23, 2631–2641 (1993).
  Article CAS PubMed Google Scholar
• Hurtado, J.C., Kim, Y.J. & Kwon, B.S. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158, 2600–2609 (1997).
  CAS PubMed Google Scholar
• Hurtado, J.C., Kim, S.H., Pollok, K.E., Lee, Z.H. & Kwon, B.S. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J. Immunol. 155, 3360–3367 (1995).
  CAS PubMed Google Scholar
• Saoulli, K. et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187, 1849–1862 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Shuford, W.W. et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186, 47–55 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Takahashi, C., Mittler, R.S. & Vella, A.T. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162, 5037–5040 (1999).
  CAS PubMed Google Scholar
• Tan, J.T. et al. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J. Immunol. 164, 2320–2325 (2000).
  Article CAS PubMed Google Scholar
• Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682–685 (1997).
  Article CAS PubMed Google Scholar
• Melero, I. et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28, 1116–1121 (1998).
  Article CAS PubMed Google Scholar
• DeBenedette, M.A., Shahinian, A., Mak, T.W. & Watts, T.H. Costimulation of CD28− T lymphocytes by 4–1BB ligand. J. Immunol. 158, 551–559 (1997).
  CAS PubMed Google Scholar
• Guinn, B.A., DeBenedette, M.A., Watts, T.H. & Berinstein, N.L. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol. 162, 5003–5010 (1999).
  CAS PubMed Google Scholar
• Latouche, J.B. & Sadelain, M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat. Biotechnol. 18, 405–409 (2000).
  Article CAS PubMed Google Scholar
• Prakken, B. et al. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. Nat. Med. 6, 1406–1410 (2000).
  Article CAS PubMed Google Scholar
• Almand, B. et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755–1766 (2000).
  CAS PubMed Google Scholar
• Rosenberg, S.A. et al. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570–578 (1990).
  Article CAS PubMed Google Scholar
• Dudley, M.E. et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24, 363–373 (2001).
  Article CAS PubMed Google Scholar
• Yee, C., Riddell, S.R. & Greenberg, P.D. In vivo tracking of tumor-specific T cells. Curr. Opin. Immunol. 13, 141–146 (2001).
  Article CAS PubMed Google Scholar
• Rooney, C.M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998).
  CAS PubMed Google Scholar
• Lord, J.D., McIntosh, B.C., Greenberg, P.D. & Nelson, B.H. The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc. J. Immunol. 161, 4627–4633 (1998).
  CAS PubMed Google Scholar
• Dahl, A.M. et al. Expression of bcl-X(L) restores cell survival, but not proliferation of effector differentiation, in CD28-deficient T lymphocytes. J. Exp. Med. 191, 2031–2038 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Dunbar, P.R. et al. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol. 8, 413–416 (1998).
  Article CAS PubMed Google Scholar
• Yee, C., Savage, P.A., Lee, P.P., Davis, M.M. & Greenberg, P.D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide–MHC tetramers. J. Immunol. 162, 2227–2234 (1999).
  CAS PubMed Google Scholar
• Curtsinger, J.M., Lins, D.C. & Mescher, M.F. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C−) to TCR/CD8 signaling in response to antigen. J. Immunol. 160, 3236–3243 (1998).
  CAS PubMed Google Scholar
• Sagerstrom, C.G., Kerr, E.M., Allison, J.P. & Davis, M.M. Activation and differentiation requirements of primary T cells in vitro. Proc. Natl. Acad. Sci. USA 90, 8987–8991 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, B., Maile, R., Greenwood, R., Collins, E.J. & Frelinger, J.A. Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells. J. Immunol. 164, 1216–1222 (2000).
  Article CAS PubMed Google Scholar
• Voltz, R. et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N. Engl. J. Med. 340, 1788–1795 (1999).
  Article CAS PubMed Google Scholar
• Tan, E.M. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J. Clin. Invest 108, 1411–1415 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• June, C.H., Ledbetter, J.A., Gillespie, M.M., Lindsten, T. & Thompson, C.B. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell Biol. 7, 4472–4481 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Riley, J.L. et al. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J. Immunol. 166, 4943–4948 (2001).
  Article CAS PubMed Google Scholar
• Claret, E.J. et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J. Clin. Invest 100, 855–866 (1997).
  Article CAS PubMed PubMed Central Google Scholar